scPharmaceuticals Inc expected to post a loss of 40 cents a share - Earnings Preview
06/08/2024 14:02
* scPharmaceuticals Inc SCPH.OQ SCPH.O is expected
to show a
rise in quarterly revenue when it reports results on August 8
(estimated) for the period ending June 30 2024
* The Burlington Massachusetts-based company is expected to
report a 393.7% increase in revenue to $8.087 million from $1.64
million a year ago, according to the mean estimate from 6
analysts, based on LSEG data.
* LSEG's mean analyst estimate for scPharmaceuticals Inc is
for a
loss of 40 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for
scPharmaceuticals
Inc is $19.00, above its last closing price of $4.20.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Mar. 31 2024 -0.44 -0.44 -0.36 Beat 17.6
Jan. 1 2024 -0.52 -0.42 -0.35 Beat 16.4
Sep. 30 2023 -0.36 -0.41 Missed -12.4
Jun. 30 2023 -0.37 -0.37 -0.36 Beat 3.3
Jan. -0.39 -0.36 -0.30 Beat 17.8
1 0001
Dec. 31 2022 -0.34 -0.39 -0.30 Beat 22.5
Jan. 1 0001 -0.36 -0.38 -0.37 Beat 3.3
Jun. 30 2022 -0.30 -0.30 -0.35 Missed -15.4
This summary was machine generated August 6 at 13:02 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)